Signal Transduction and Targeted Therapy (Aug 2021)

VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance

  • Weiling Liu,
  • Chuanwang Miao,
  • Shaosen Zhang,
  • Yachen Liu,
  • Xiangjie Niu,
  • Yiyi Xi,
  • Wenjia Guo,
  • Jiahui Chu,
  • Ai Lin,
  • Hongjin Liu,
  • Xinyu Yang,
  • Xinjie Chen,
  • Ce Zhong,
  • Yuling Ma,
  • Yuqian Wang,
  • Shihao Zhu,
  • Shuning Liu,
  • Wen Tan,
  • Dongxin Lin,
  • Chen Wu

DOI
https://doi.org/10.1038/s41392-021-00735-9
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Radiotherapy remains the mainstay for treatment of various types of human cancer; however, the clinical efficacy is often limited by radioresistance, in which the underlying mechanism is largely unknown. Here, using esophageal squamous cell carcinoma (ESCC) as a model, we demonstrate that guanine nucleotide exchange factor 2 (VAV2), which is overexpressed in most human cancers, plays an important role in primary and secondary radioresistance. We have discovered for the first time that VAV2 is required for the Ku70/Ku80 complex formation and participates in non-homologous end joining repair of DNA damages caused by ionizing radiation. We show that VAV2 overexpression substantially upregulates signal transducer and activator of transcription 1 (STAT1) and the STAT1 inhibitor Fludarabine can significantly promote the sensitivity of radioresistant patient-derived ESCC xenografts in vivo in mice to radiotherapy. These results shed new light on the mechanism of cancer radioresistance, which may be important for improving clinical radiotherapy.